Skip to main content
Original Research, Antibiotics, Infections, Adverse Events, Oncology Pharmacy Programs/Protocols
Retrospective Evaluation of Initial Empiric Double Coverage with Tobramycin in Adult Patients with Febrile Neutropenia
Amber B. Clemmons, PharmD, BCOP, FHOPA; Rachel Shelley, PharmD; Vayou Chittavong, MS, PharmD; Huimin Hu, PhD; Xianyan Chen, PhD; Joshua Eudy, PharmD, BCIDP; Andrew Chao, MD; Daniel T. Anderson, PharmD, BCIDP
Read More
ASCO 2023 Highlights
Zanidatamab Plus Docetaxel Shows Promising Antitumor Activity in Advanced HER2-Positive Breast Cancer
Read More
ASCO 2023 Highlights
Prolonged Effectiveness With Tucatinib Plus Trastuzumab and Capecitabine in HER2-Positive Metastatic Breast Cancer
Read More
ASCO 2023 Highlights
Inetetamab Plus Camrelizumab and Utidelone Safe and Effective in Patients With HER2-Positive Metastatic Breast Cancer
Read More
ASCO 2023 Highlights
Dalpiciclib Plus Pyrotinib Prolongs Survival in Patients With HER2-Positive Advanced Breast Cancer
Read More
ASCO 2023 Highlights
Neratinib Plus Trastuzumab Emtansine in Patients With HER2-Positive Breast Cancer and Molecular Residual Disease
Read More
ASCO 2023 Highlights
Anti-HER2/HER3 αDC1 Vaccines Plus Pembrolizumab for Brain Metastases in Patients With Triple-Negative or HER2-Positive Breast Cancer
Read More
ASCO 2023 Highlights
Strong Antitumor Activity With Neoadjuvant Intratumoral Dendritic Cell Vaccine Therapy Plus Paclitaxel, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer
Read More
ASCO 2023 Highlights
Phase 1b/2 Trial of Ribociclib, Tucatinib, and Trastuzumab to Find Chemotherapy-Free Treatment Combination Regimens for HER2-Positive Breast Cancer
Read More
ASCO 2023 Highlights
Dalpiciclib Plus Pyrotinib and Endocrine Therapy Shows Promising Antitumor Activity in ER-Positive, HER2-Positive Metastatic Breast Cancer
Read More
Page 35 of 199
Results 341 - 350 of 1986